<code id='30039123A3'></code><style id='30039123A3'></style>
    • <acronym id='30039123A3'></acronym>
      <center id='30039123A3'><center id='30039123A3'><tfoot id='30039123A3'></tfoot></center><abbr id='30039123A3'><dir id='30039123A3'><tfoot id='30039123A3'></tfoot><noframes id='30039123A3'>

    • <optgroup id='30039123A3'><strike id='30039123A3'><sup id='30039123A3'></sup></strike><code id='30039123A3'></code></optgroup>
        1. <b id='30039123A3'><label id='30039123A3'><select id='30039123A3'><dt id='30039123A3'><span id='30039123A3'></span></dt></select></label></b><u id='30039123A3'></u>
          <i id='30039123A3'><strike id='30039123A3'><tt id='30039123A3'><pre id='30039123A3'></pre></tt></strike></i>

          focus

          focus

          author:Wikipedia    Page View:6627
          Illustration of a person talking with a huge speech bubble over his head. -- health tech coverage from STAT
          Mike Reddy for STAT

          The health care sector is a notorious laggard when it comes to technology. It was slow to use computers, digitize patient data, and share information electronically. While most of the world instantly interacts via Zoom and Slack, hospitals — even today — are still sending faxes.

          But something different is happening with generative AI.

          advertisement

          Health systems, drugmakers, and insurers are racing to build the technology into their operations, aligning themselves with corporate giants such as Microsoft, Google, and Nvidia, whose executives speak about each incremental advancement of AI as an earth-shattering event. “The generative AI revolution is here,” Jensen Huang, 61, Nvidia’s leather-jacket-clad CEO, declared during the company’s GTC conference in San Jose, Calif., last week.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Ventyx halts psoriasis drug development after lackluster trial results
          Ventyx halts psoriasis drug development after lackluster trial results

          AdobeSANDIEGO—VentyxBiosciencesreportedonMondaythatitwasendingdevelopmentofanexperimentaldrugfortrea

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Pfizer's Covid pill remains 89% effective in final analysis, company says

          Paxlovid,Pfizer'spilltotreatCovid-19PfizerPaxlovid,Pfizer’spilltotreatCovid-19,retainedits89%efficac